Background: Medicines for the treatment of 2019-novel coronavirus (2019-nCoV) infections are urgently needed. However, drug screening using live 2019-nCoV requires high-level biosafety facilities, which imposes an obstacle for those without such facilities or 2019-novel coronavirus (2019-nCoV). This study aims to repurpose the clinically approved drugs for the treatment of coronavirus disease 2019 (COVID-19) in a 2019-nCoV related coronavirus model.
Introduction
The coronavirus disease 2019 (COVID- 19) , which is caused by 2019 novel coronavirus (2019-nCoV) and was first detected in Wuhan, China in December 2019, imposes a grand immediate challenge for global public health. [1, 2] So far, COVID-19 has spread to many other countries with thousands of infected cases. In the major affected area, the mainland of China, the death toll and the number of confirmed cases are still growing. There is an urgent need for effective vaccines and specific therapies for the prevention and treatment of 2019-nCoV infection.
A coronavirus closely related to 2019-nCoV was identified in a sample collected from Rhinolophus affinis bat in Yunnan in 2013, suggesting bats are likely the reservoirs of 2019-nCoV. [3] Recently, the searching of reservoirs or intermediate hosts of 2019-nCoV turned to pangolins. Xiao et al [4] reported the isolation and characterization of a 2019-nCoV-like coronavirus from pangolins (Manis javanica). Similarly, in October 2019, a viral metagenomic study of pangolins identified severe acute respiratory syndrome-coronavirus (SARS-CoV) related sequences, [5] which can be re-identified as 2019-nCoV related sequences. [6] Moreover, we also reported the isolation and identification of 2019-nCoV related coronaviruses in pangolins seized in anti-smuggling operations in southern China. [7] Altogether, pangolins are likely a reservoir or an intermediate host of 2019-nCoV. [5] Due to its pathogenicity and transmissibility of 2019-nCoV, working with live 2019-nCoV requires high-level biocontainment facilities, which impedes the urgent needs for drug screening.
Without prior experience of therapy, the current treatment of 2019-nCoV infection is mainly empirical and symptomatic, and a limited number of therapeutics in ongoing clinical trial were adopted from previous research with SARS-CoV and Middle East respiratory syndromecoronavirus (MERS-CoV), which are only remotely related with 2019-nCoV. With low or no pathogenicity in humans and close genetic relationship with 2019-nCoV, our pangolin coronavirus provides an ideal alternative model for 2019-nCoV research. Our reasoning of this isolate having low or no pathogenicity in human was based on the fact that, back in 2017, no suspected infections were found in those having close contacts with pangolins; and our pangolin coronavirus isolate was routinely cultured in biosafety level 2 facilities. Here we present a screening of clinically approved drugs for anti-coronavirus activity in this 2019-nCoV related coronavirus model, and identify the potent inhibitors for pangolin coronavirus infection.
Methods

Cell lines, coronavirus and key reagents
Vero E6 cells (American Type Culture Collection, Manassas, VA, USA) were grown in highglucose-containing Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum (FBS). 2019-nCoV related coronavirus (2019-nCoVr) GX_P2V/pangolin/2017/Guangxi was isolated in Vero E6 cells from a dead smuggled pangolin in 2017, and its complete genome has been submitted to GenBank. [7] A library of 2080 approved drugs (catalog No. L1000) and a library of 326 anti-virus compounds (catalog No. L1700) produced by TargetMol were purchased from Topscience (Shanghai, China). Oligonucleotides used in the study can be found in Supplementary Table 1 , http://links.lww.com/CM9/A216.
Plaque assay for determining virus titer
Confluent monolayer Vero E6 cells were infected with serially 10-fold diluted 2019-nCoVr, at a range of 10 −1 to 10 −6 . At 2 h post infection (p.i.), the virus was removed and the cells were washed twice with phosphate buffered saline (PBS). And then 3 mL 1% agarose overlay was added to each well to prevent cross-contamination. At 3 d p.i. or 5 d p.i., cells were fixed with 4% paraformaldehyde for 1 h at room temperature. Then the upper semi-solid agarose medium was removed. Fixed cells were stained with crystal violet for 10 min, and rinsed with water gently for several times. The number of plaques was counted and virus titers were calculated.
siRNA-mediated silencing of ACE2
Vero E6 cells were transfected with 0.8, 4 and 20 nmol/L angiotensin-converting enzyme 2 (ACE2)-specific siRNApool (siACE2) or negative control siRNA (siNC) by using the RNAiMax transfection reagent (Invitrogen, Carlsbad, CA, USA) as previously described. [8] 
Drug screening for 2019-nCoVr using approved drug library
Vero E6 cells were plated in 96 well plates at a density of 2.5×10 4 cells/well. Cells were treated with 2019-nCoVr (MOI=0.01) and different chemical drugs of the approved drug library with the final concentration of 10 μmol/L. At 2 h p.i., 2019-nCoVr and drugs were removed, and fresh culture medium containing 10 μmol/L drugs were added to each well. At 72 h p.i, the cytopathic effect (CPE) was observed using microscopy (Nikon, Cat:TS100 and TS2-S-SM, Tokyo, Japan).
And the cells in the wells without obvious CPE were further analyzed.
Viral RNA extraction and qRT-PCR
Cell culture supernatants and Vero E6 cells were harvested for RNA extraction using the Table 1 , http://links.lww.com/CM9/A216. And the PCR products were inserted into T vector (Ruibo Xingke Biotech, Beijing, China) to generate the standard plasmid after sequencing confirmation. The standard curve was generated by determination of copy numbers from serially dilutions (10 3 −10 9 copies) of the plasmid. qRT-PCR amplification of SYBR Green method was performed as follows: 95 °C for 5 min followed by 40 cycles consisting of 95 °C for 10 s, 55 °C for 20 s, and 72 °C for 31 s. And the Taqman method was performed as follows: 50 °C for 2 min, 95 °C for 10 min followed by 40 cycles consisting of 95 °C for 10 s, 60 °C for 1 min.
Time-of-addition experiment of cepharanthine (CEP)
The CEP (10 μmol/L) was used for the time of addition experiment. Vero E6 cells (5×10 4 cells/well) were plated in 12 well plates and treated with CEP at different stages of virus infection. The "Full time" treatment, "Entry" treatment and "Post entry" treatment experiments were performed according to a previous study. [9] And the cytotoxicity of CEP to Vero E6 cells was measured by cell titer blue according to the manufacturer's protocol (Promega, Catalog Number: PR-G8081; Madison, WI, USA).
Statistical analysis
The data were analyzed using GraphPad Prism 8 software (GraphPad Software Inc, San Diego, CA, USA) and presented as the mean ± standard deviation (normal distribution of data was checked by Kolmogorov-Smirnov test). Comparisons between the two groups were analyzed using the student's t tests. A P value of < 0.05 was considered statistically significant.
Results
Pangolin coronavirus isolate GX_P2V is as an alternative model for 2019-nCoV research
We reported the identification of 2019-nCoV related coronaviruses, which were composed of a lineage of 2019-nCoV and coronaviruses found in eight pangolin samples and three bat samples. [7] Our GX_P2V isolate is hitherto one of the few 2019-nCoV related coronaviruses cultured from wildlife. Its spike protein shares 92.2% amino acid identity with the spike protein of 2019-nCoV isolate Wuhan-hu-1. Their major differences are in the S1 domain, especially the receptor binding domain (RBD). Alignment of the receptor binding motifs of the 2019-nCoV related lineage revealed a surprising diversity in the five critical residues for postulated binding between coronavirus RBD and human ACE2 protein [ Figure 1A ]. Compared to the five critical residues in SARS-CoV, two in GX_P2V and four in 2019-nCoV are replaced with different residues.
Angiotensin converting enzyme II (ACE2) is the cell receptor for both SARS-CoV, bat SARSlike CoV, and 2019-nCoV. [3, 10, 11] We next tested whether ACE2 is involved in pangolin CoV GX_P2V infection by using siRNA-mediated knockdown of ACE2 expression. In Vero E6 cells treated with 0.8 nmol/L, 4 nmol/L and 20 nmol/L concentrations of ACE2-targeting siRNAs, the yields of ACE2 mRNA and viral RNA are all significantly reduced, suggesting that ACE2 expression was knocked down by siRNA [ Figure 1B ] and ACE2 is also a receptor of 2019-nCoVr GX_P2V [ Figure 1C ]. It appears that ACE2 is a conserved receptor of both SARS-CoV and 2019-nCoV related viruses. It is noted, however, that having a possible receptor of ACE2 does not correlate to viral pathogenicity. In fact, no human infections relating to our pangolin CoV was identified or suspected, suggesting that CoV GX_P2V is nonpathogenic in human.
Altogether, the close relationship to 2019-nCoV, the shared receptor and non-pathogenicity, support that pangolin CoV GX_P2X can be used as an accessible in vitro model for developing therapies against 2019-nCoV.
Three drugs are potent inhibitors of 2019-nCoVr infection
In our 2019-nCoVr and Vero E6 cell model, we first screened a total of 2406 drugs and compounds for their inhibitory effects on viral infection-dependent CPE in 96 well plates [ Figure   2A ]. Each drug or compound was added to 10 μmol/L at the starting time point of infection and all drugs were tested in duplicate. At 72 h p.i., cells were observed under phase microscopy.
Infected cells without any drug treatment showed typical CPE-cell rounding with no obvious lysis. Importantly, three drugs-CEP, selamectin and mefloquine hydrochloride, exhibited complete inhibition of CPE in infected cells [ Supplementary Figure 1 Among the three drug candidates, CEP is of particular attention due to its profound antiviral activity and previous reports of its inhibitory effects on both SARS-CoV and HCoV-OC43. [12, 13] It can inhibit 2019-nCoVr at a low concentration (concentration for 50% of maximal effect Figure 3A ]. We next investigated this drug's antiviral mechanism by conducting viral entry, post-entry and full-time assays in 12 well plates [ Figure 3B ]. In the viral entry assay, cells were incubated with media containing both viruses and CEP during the first 2 h of infection, then were washed with PBS and were supplemented with media containing no drugs.
In the viral post-entry assay, cells were incubated in media containing no CEP during the first 2 h of infection, then were supplemented with media containing CEP. In the viral full-time assay, cells were constantly incubated in media containing CEP. Viral RNA yields were determined by Figure 3C ].
Thus, our data suggest that CEP can potently inhibit coronavirus infection at viral entry and post-entry.
Discussion
Here we first described a 2019-nCoV related coronavirus model for research of 2019-nCoV. This model is suitable for work at biosafety level-2. We then identified three clinically approved drugs (CEP, selamectin and mefloquine hydrochloride) that can inhibit a 2019-nCoV related coronavirus infection, and suggest that these drugs be considered for clinical trials in 2019-nCoV patients.
Our finding of CEP as a potential drug for 2019-nCoV is especially instructive. This drug is an anti-inflammatory and antineoplastic alkaloid and is approved for leukopenia. It has multiple functions, such as inhibiting the efflux transporter ABCC10 of antitumor drugs, [14] inhibiting the entry of human immunodeficiency virus type 1 (HIV-1) by reducing plasma membrane fluidity, [15] and binding to central portion of Hsp90. [16] Importantly, as a naturally occurring plant alkaloid with more than 40 years of clinic use, CEP has low toxicity in animals and has no significant side effects in human. [17, 18] Given the observed strong inhibition of virus replication and the drug's established role of anti-inflammatory response, we think CEP is a promising candidate for treatment of 2019-nCoV infection.
Nonetheless, our finding of CEP and mefloquine as anti-2019-nCoVr agents was in agreement with previous studies in other coronaviruses of the genus Betacoronavirus. Two groups reported CEP as a drug candidate for SARS-CoV and HCoV-OC43, respectively. [12, 13] Mefloquine, which is approved for malaria, was found to have antiviral activity against both MERS-CoV and SARS-CoV. [19] Furthermore, we identified a previously unknown anti-CoV compoundselamectin, which is marketed as a topical broad-spectrum parasiticide in cats and dogs to control fleas, heartworms, hookworms, roundworms, etc. The antiviral mechanisms of these three drugs are unknown. We speculate that CEP and mefloquine are likely to target host cell pathways while selamectin might be a 2019-nCoVr specific inhibitor.
The libraries of drugs used in this study contain 2406 compounds in total. Many of them have antiviral activities against MERS-CoV and SARS-CoV. [19] Clearly, our finding of only three inhibitors of 2019-nCoVr is not a comprehensive answer of all potential inhibitors in our libraries, as our goal is to find drugs that have the most potent antiviral activities and we did the initial screening of virus inhibition by observing the existence of intact cell monolayers, not by quantitative methods.
In conclusion, this is the first report of a 2019-nCoV related coronavirus model. We suggest the three drugs (CEP, selamectin and mefloquine hydrochloride) be considered for trials in 2019- 
